Search

Your search keyword '"Wester, Hans-Jürgen"' showing total 1,395 results
Start Over Author "Wester, Hans-Jürgen"
1,395 results on '"Wester, Hans-Jürgen"'

3. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.

Author

Fendler, Wolfgang P, Eiber, Matthias, Beheshti, Mohsen, Bomanji, Jamshed, Calais, Jeremie, Ceci, Francesco, Cho, Steve Y, Fanti, Stefano, Giesel, Frederik L, Goffin, Karolien, Haberkorn, Uwe, Jacene, Heather, Koo, Phillip J, Kopka, Klaus, Krause, Bernd J, Lindenberg, Liza, Marcus, Charles, Mottaghy, Felix M, Oprea-Lager, Daniela E, Osborne, Joseph R, Piert, Morand, Rowe, Steven P, Schöder, Heiko, Wan, Simon, Wester, Hans-Jürgen, Hope, Thomas A, and Herrmann, Ken

Subjects
Humans, Prostatic Neoplasms, Gallium Radioisotopes, Edetic Acid, Oligopeptides, Male, Positron Emission Tomography Computed Tomography, Guideline, PET, PSMA, Prostate cancer, Restaging, Staging, Biomedical Imaging, Urologic Diseases, Aging, Prostate Cancer, Cancer, Other Physical Sciences, Clinical Sciences, Nuclear Medicine & Medical Imaging
Abstract

Here we aim to provide updated guidance and standards for the indication, acquisition, and interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics are reported for a variety of available PSMA small radioligands. Different scenarios for the clinical use of PSMA-ligand PET/CT are discussed. This document provides clinicians and technicians with the best available evidence, to support the implementation of PSMA PET/CT imaging in research and routine practice.

Published
2023

14. Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [68Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer

Author

Günther, Thomas, primary, Holzleitner, Nadine, additional, Viering, Oliver, additional, Beck, Roswitha, additional, Wienand, Georgine, additional, Dierks, Alexander, additional, Pfob, Christian H., additional, Bundschuh, Ralph A., additional, Kircher, Malte, additional, Lapa, Constantin, additional, and Wester, Hans-Jürgen, additional

Published
2023
Full Text
View/download PDF

19. 68Ga-PSMA I&T PET/CT for primary staging of prostate cancer

Author

Cytawa, Wojciech, Seitz, Anna Katharina, Kircher, Stefan, Fukushima, Kazuhito, Tran-Gia, Johannes, Schirbel, Andreas, Bandurski, Tomasz, Lass, Piotr, Krebs, Markus, Połom, Wojciech, Matuszewski, Marcin, Wester, Hans-Jürgen, Buck, Andreas K., Kübler, Hubert, and Lapa, Constantin

Published
2020
Full Text
View/download PDF

20. Biodistribution and Radiation Dosimetry for a Probe Targeting Prostate-Specific Membrane Antigen for Imaging and Therapy

Author

Herrmann, Ken, Bluemel, Christina, Weineisen, Martina, Schottelius, Margret, Wester, Hans-Jürgen, Czernin, Johannes, Eberlein, Uta, Beykan, Seval, Lapa, Constantin, Riedmiller, Hubertus, Krebs, Markus, Kropf, Saskia, Schirbel, Andreas, Buck, Andreas K, and Lassmann, Michael

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Prostate Cancer, Urologic Diseases, Biomedical Imaging, Bioengineering, Cancer, Aged, Antigens, Surface, Bone Marrow, Edetic Acid, Gallium Isotopes, Gallium Radioisotopes, Glutamate Carboxypeptidase II, Humans, Kidney, Male, Middle Aged, Oligopeptides, Positron-Emission Tomography, Prostatic Neoplasms, Radiometry, Radiopharmaceuticals, Salivary Glands, Spleen, Tissue Distribution, Whole Body Imaging, PET, PSMA, Ga-68, dosimetry, prostate cancer, 68Ga, Nuclear Medicine & Medical Imaging, Clinical sciences
Abstract

UnlabelledProstate-specific membrane antigen (PSMA) is a promising target for diagnosis and treatment of prostate cancer. EuK-Subkff-(68)Ga-DOTAGA ((68)Ga-PSMA Imaging & Therapy [PSMA I&T]) is a recently introduced PET tracer for imaging PSMA expression in vivo. Whole-body distribution and radiation dosimetry of this new probe were evaluated.MethodsFive patients with a history of prostate cancer were injected intravenously with 91-148 MBq of (68)Ga-PSMA I&T (mean ± SD, 128 ± 23 MBq). After an initial series of rapid whole-body scans, 3 static whole-body scans were acquired at 1, 2, and 4 h after tracer injection. Time-dependent changes of the injected activity per organ were determined. Mean organ-absorbed doses and effective doses were calculated using OLINDA/EXM.ResultsInjection of 150 MBq of (68)Ga-PSMA I&T resulted in an effective dose of 3.0 mSv. The kidneys were the critical organ (33 mGy), followed by the urinary bladder wall and spleen (10 mGy each), salivary glands (9 mGy each), and liver (7 mGy).Conclusion(68)Ga-PSMA I&T exhibits a favorable dosimetry, delivering organ doses that are comparable to (kidneys) or lower than those delivered by (18)F-FDG.

Published
2015

21. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)

Author

Kratochwil, Clemens, Fendler, Wolfgang Peter, Eiber, Matthias, Baum, Richard, Bozkurt, Murat Fani, Czernin, Johannes, Delgado Bolton, Roberto C., Ezziddin, Samer, Forrer, Flavio, Hicks, Rodney J., Hope, Thomas A., Kabasakal, Levant, Konijnenberg, Mark, Kopka, Klaus, Lassmann, Michael, Mottaghy, Felix M., Oyen, Wim, Rahbar, Kambiz, Schöder, Heiko, Virgolini, Irene, Wester, Hans-Jürgen, Bodei, Lisa, Fanti, Stefano, Haberkorn, Uwe, and Herrmann, Ken

Published
2019
Full Text
View/download PDF

24. Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies.

Author

Wurzer, Alexander, De Rose, Francesco, Fischer, Sebastian, Schwaiger, Markus, Weber, Wolfgang, Nekolla, Stephan, Wester, Hans-Jürgen, Eiber, Matthias, and D'Alessandria, Calogero

Subjects
MEDICAL dosimetry, PROSTATE cancer, SERUM albumin, EXTERNAL beam radiotherapy, STEREOISOMERS, ISOMERS
Abstract

Background: Radiohybrid PSMA-targeted ligands (rhPSMA) have been introduced as a novel platform for theranostic applications. Among a variety of rhPSMA-ligands developed for radioligand therapy, two stereoisomers [177Lu]Lu-rhPSMA-10.1 and -10.2 have been synthesized and initially characterized in preclinical experiments with the aim to provide an optimized binding profile to human serum albumin, a reduction of charge, and thus accelerated kidney excretion, and unaffected or even improved tumor uptake. As both isomers showed similar in vitro characteristics and tumor uptake at 24 h post injection in tumor bearing mice and in order to identify the isomer with the most favorable pharmacokinetics for radioligand therapy, we carried out in-depth biodistribution and dosimetry studies in tumor-bearing and healthy mice. Results: rhPSMA-10.1 and -10.2 were radiolabeled with lutetium-177 according to the established procedures of other DOTA-based PSMA ligands and displayed a high and comparable stability in all buffers and human serum (> 97%, 24 h). Biodistribution studies revealed fast clearance from the blood pool (0.3–0.6%ID/g at 1 h) and other background tissues within 48 h. Distinctive differences were found in the kidneys, where [177Lu]Lu-rhPSMA-10.1 displayed lower initial uptake and faster excretion kinetics compared to [177Lu]Lu-rhPSMA-10.2 expressed by a 1.5-fold and ninefold lower uptake value at 1 h and 24 h in healthy animals, respectively. Tumor uptake was comparable and in the range of 8.6–11.6%ID/g for both isomers over 24 h and was maintained up to 168 h at a level of 2.2 ± 0.8 and 4.1 ± 1.4%ID/g for [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2, respectively. Conclusion: Our preclinical data on biodistribution and dosimetry indicate a more favorable profile of [177Lu]Lu-rhPSMA-10.1 compared to [177Lu]Lu-rhPSMA-10.2 for PSMA-targeted radioligand therapy. [177Lu]Lu-rhPSMA-10.1 shows fast kidney clearance kinetics resulting in excellent tumor-to-organ ratios over a therapy relevant time course. Meanwhile, [177Lu]Lu-rhPSMA-10.1 is currently being investigated in clinical phase I/II studies in patients with mCRPC (NCT05413850), in patients with high-risk localized PC (NCT06066437, Nautilus Trial) and after external beam radiotherapy (NCT06105918). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography, histopathology and immunohistochemistry in primary prostate cancer

Author

Wang, Hui, primary, Remke, Marianne, additional, Horn, Thomas, additional, Schwamborn, Kristina, additional, Chen, Yiyao, additional, Steiger, Katja, additional, Weichert, Wilko, additional, Wester, Hans-Jürgen, additional, Schottelius, Margret, additional, Weber, Wolfgang, additional, and Eiber, Matthias, additional

Published
2023
Full Text
View/download PDF

27. Preclinical Comparison of the64Cu- and68Ga-Labeled GRPR-Targeted Compounds RM2 and AMTG, as Well as First-in-Humans [68Ga]Ga-AMTG PET/CT

Author

Koller, Lena, primary, Joksch, Markus, additional, Schwarzenböck, Sarah, additional, Kurth, Jens, additional, Heuschkel, Martin, additional, Holzleitner, Nadine, additional, Beck, Roswitha, additional, von Amsberg, Gunhild, additional, Wester, Hans-Jürgen, additional, Krause, Bernd Joachim, additional, and Günther, Thomas, additional

Published
2023
Full Text
View/download PDF

29. Comparison of 68 Ga-PSMA ligand PET/CT versus conventional cross-sectional imaging for target volume delineation for metastasis-directed radiotherapy for metachronous lymph node metastases from prostate cancer

Author

Walacides, Daniel, Meier, Astrid, Knöchelmann, Anne Caroline, Meinecke, Daniele, Derlin, Thorsten, Bengel, Frank M., Ross, Tobias L., Wester, Hans-Jürgen, Derlin, Katja, Kuczyk, Markus A., von Klot, Christoph A. J., Christiansen, Hans, and Henkenberens, Christoph

Published
2019
Full Text
View/download PDF

31. Imaging of chemokine receptor CXCR4 expression in culprit and nonculprit coronary atherosclerotic plaque using motion-corrected [68Ga]pentixafor PET/CT

Author

Derlin, Thorsten, Sedding, Daniel G., Dutzmann, Jochen, Haghikia, Arash, König, Tobias, Napp, L. Christian, Schütze, Christian, Owsianski-Hille, Nicole, Wester, Hans-Jürgen, Kropf, Saskia, Thackeray, James T., Bankstahl, Jens P., Geworski, Lilli, Ross, Tobias L., Bauersachs, Johann, and Bengel, Frank M.

Published
2018
Full Text
View/download PDF

33. Somatostatin receptors in GtoPdb v.2023.1

Author

Bosquet, Corinne, primary, Castaño, Justo P., primary, Csaba, Zsolt, primary, Culler, Micheal, primary, Dournaud, Pascal, primary, Epelbaum, Jacques, primary, Feniuk, Wasyl, primary, Harmar, Anthony, primary, Hills, Rebecca, primary, Hofland, Leo, primary, Hoyer, Daniel, primary, Humphrey, Patrick P. A., primary, Kreienkamp, Hans-Jürgen, primary, Lupp, Amelie, primary, Melmed, Shlomo, primary, Meyerhof, Wolfgang, primary, O'Carroll, Anne-Marie, primary, Patel, Yogesh C., primary, Reisine, Terry, primary, Reubi, Jean-Claude, primary, Schindler, Marcus, primary, Schmid, Herbert, primary, Schonbrunn, Agnes, primary, Schulz, Stefan, primary, Taylor, John E., primary, Tulipano, Giovanni, primary, Vezzani, Annamaria, primary, and Wester, Hans-Jürgen, primary

Published
2023
Full Text
View/download PDF

39. [99mTc]Tc-PentixaTec: development, extensive pre-clinical evaluation, and first human experience.

Author

Konrad, Matthias, Rinscheid, Andreas, Wienand, Georgine, Nittbaur, Bernd, Wester, Hans-Jürgen, Janzen, Tilman, Lapa, Constantin, Pfob, Christian Helmut, and Schottelius, Margret

Subjects
RADIATION dosimetry, COMPUTED tomography, SINGLE-photon emission computed tomography, CXCR4 receptors, RADIONUCLIDE imaging, HEMATOLOGIC malignancies
Abstract

Purpose: The clinical success non-invasive imaging of CXCR4 expression using [68 Ga]Ga-PentixaFor-PET warrants an expansion of the targeting concept towards conventional scintigraphy/SPECT with their lower cost and general availability. To this aim, we developed and comparatively evaluated a series of 99mTc-labeled cyclic pentapeptides based on the PentixaFor scaffold. Methods: Six mas3-conjugated CPCR4 analogs with different 4-aminobenzoic acid (Abz)-D-Ala-D-Arg-aa3 linkers (L1–L6) as well as the corresponding HYNIC- and N4-analogs of L6-CPCR4 were synthesized via standard SPPS. Competitive binding studies (IC50 and IC50inv) were carried out using Jurkat T cell lymphoma cells and [125I]FC-131 as radioligand. Internalization kinetics were investigated using hCXCR4-overexpressing Chem-1 cells. Biodistribution studies and small animal SPECT/CT imaging (1 h p.i.) were carried out using Jurkat xenograft bearing CB17/SCID mice. Based on the preclinical results, [99mTc]Tc-N4-L6-CPCR4 ([99mTc]Tc-PentixaTec) was selected for an early translation to the human setting. Five patients with hematologic malignancies underwent [99mTc]Tc-N4-L6-CPCR4 SPECT/planar imaging with individual dosimetry. Results: Of the six mas3-conjugated peptides, mas3-L6-CPCR4 (mas3-dap-r-a-Abz-CPCR4) showed the highest CXCR4 affinity (IC50 = 5.0 ± 1.3 nM). Conjugation with N4 (N4-L6-CPCR4) further improved hCXCR4 affinity to 0.6 ± 0.1 nM. [99mTc]Tc-N4-L6-CPCR4 also showed the most efficient internalization (97% of total cellular activity at 2 h) and the highest tumor accumulation (8.6 ± 1.3% iD/g, 1 h p.i.) of the compounds investigated. Therefore, [99mTc]Tc-N4-L6-CPCR4 (termed [99mTc]Tc-PentixaTec) was selected for first-in-human application. [99mTc]Tc-PentixaTec was well tolerated, exhibits a favorable biodistribution and dosimetry profile (2.1–3.4 mSv per 500 MBq) and excellent tumor/background ratios in SPECT and planar imaging. Conclusion: The successive optimization of the amino acid composition of the linker structure and the N-terminal 99mTc-labeling strategies (mas3 vs HYNIC vs N4) has provided [99mTc]Tc-PentixaTec as a novel, highly promising CXCR4-targeted SPECT agent for clinical application. With its excellent CXCR4 affinity, efficient internalization, high uptake in CXCR4-expressing tissues, suitable clearance/biodistribution characteristics, and favorable human dosimetry, it holds great potential for further clinical use. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. Supplementary figure 1 from CXCR4 Is a Potential Target for Diagnostic PET/CT Imaging in Barrett's Dysplasia and Esophageal Adenocarcinoma

Author

Fang, Hsin-Yu, primary, Münch, Natasha Stephens, primary, Schottelius, Margret, primary, Ingermann, Jonas, primary, Liu, Haibo, primary, Schauer, Michael, primary, Stangl, Stefan, primary, Multhoff, Gabriele, primary, Steiger, Katja, primary, Gerngroß, Carlos, primary, Jesinghaus, Moritz, primary, Weichert, Wilko, primary, Kühl, Anja A., primary, Sepulveda, Antonia R., primary, Wester, Hans-Jürgen, primary, Wang, Timothy C., primary, and Quante, Michael, primary

Published
2023
Full Text
View/download PDF

46. Supplementary figure 2 from CXCR4 Is a Potential Target for Diagnostic PET/CT Imaging in Barrett's Dysplasia and Esophageal Adenocarcinoma

Author

Fang, Hsin-Yu, primary, Münch, Natasha Stephens, primary, Schottelius, Margret, primary, Ingermann, Jonas, primary, Liu, Haibo, primary, Schauer, Michael, primary, Stangl, Stefan, primary, Multhoff, Gabriele, primary, Steiger, Katja, primary, Gerngroß, Carlos, primary, Jesinghaus, Moritz, primary, Weichert, Wilko, primary, Kühl, Anja A., primary, Sepulveda, Antonia R., primary, Wester, Hans-Jürgen, primary, Wang, Timothy C., primary, and Quante, Michael, primary

Published
2023
Full Text
View/download PDF

47. Supplementary figure 3 from CXCR4 Is a Potential Target for Diagnostic PET/CT Imaging in Barrett's Dysplasia and Esophageal Adenocarcinoma

Author

Fang, Hsin-Yu, primary, Münch, Natasha Stephens, primary, Schottelius, Margret, primary, Ingermann, Jonas, primary, Liu, Haibo, primary, Schauer, Michael, primary, Stangl, Stefan, primary, Multhoff, Gabriele, primary, Steiger, Katja, primary, Gerngroß, Carlos, primary, Jesinghaus, Moritz, primary, Weichert, Wilko, primary, Kühl, Anja A., primary, Sepulveda, Antonia R., primary, Wester, Hans-Jürgen, primary, Wang, Timothy C., primary, and Quante, Michael, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results